Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5

Inclusion criteria

• Patients with ischemic symptoms and/or evidence of myocardial ischemia
• Presence of ≥ 50% restenosis after prior implantation of drug-eluting stents in native coronary vessels.
• Availability of an OCT-pullback of the target lesion
• Written informed consent by the patient for participation in the study.
• Age ≥ 18 years

Exclusion criteria

• Cardiogenic shock
• Acute ST-elevation myocardial infarction within 48 hours from symptom onset.
• Target lesion located in left main trunk or bypass graft.
• Additional coronary intervention planned within 30 days of the procedure.
• Non-successful treatment of other lesion(s) during the same procedure
• Severe renal insufficiency (glomerular filtration rate ≤ 30 ml/min)
• Contraindications to any components of the investigational devices or dual antiplatelet therapy
• Pregnancy (present, suspected or planned) or positive pregnancy test.
• Previous enrollment in this trial or participation in any other study at the time of enrollment.
• Malignancies or other comorbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance.
• Patient's inability to fully comply with the study protocol